Ten billion varieties 3 pharmaceutical companies review: Shuangyu, Qilu, Zhengda sunny

Pharmaceutical Network July 9th, 10 billion u.Sdollars of star varieties to nado amine, 3 domestic pharmaceutical companies through consistency evaluation1
, the rapid growth of the multi-billion dollar star varietiesrecently, Beijing Shuangyu Pharmaceuticals announced that the company's products to nadu amine capsules through consistency evaluation, after Zhengda Qing and Qilu Pharmaceuticals, the third domestic evaluation of the enterpriseShuangyu Pharmaceuticals said in the announcement, the consistency of the amine capsule scored through the consistency of the evaluation will be conducive to the replacement of the original research products, improve the market competitiveness and market share of the product, the future business performance has a positive impactPublic information shows that reinamine is a first-line drug of multiple myeloma, as a new generation of immunomodulator, with immunomodulation, anti-angiogenesis and anti-tumor characteristics, clinically widely used in multiple myeloma, lymphoma, myeloma abnormal syndrome, acute myeloid leukemia and otherdiseasestreatment, is currently the international and domestic treatment of multiple myeloma and myeloma abnormal syndrome commonly used drugsAs a heavy drug for the treatment of multiple myeloma, nardomine is a priority recommended drug in the 2018 edition of the U.SNational Comprehensive Cancer Network's Multiple Myeloma Guidelines, and is also a key drug for first-line treatment, second-line treatment and relapse in China's 2017 Multiple Myeloma Diagnosis GuideThe earliest, renado amine original research and development by the new base company, December 27, 2005 by the United States Food and Drug Administration (FDA) approved the listing, 2013 was approved to enter the Chinese market, January 23 of that year, renamelamine to "Refumei" commodity name officially listed in China, the capsule form, specifications of 5mg, 10mg, 15mg, 25mg, which 25 mg of the price of 25mg of the price of 299 99According to public data, xinji's Swiss-Fumei 2019 global sales reached $10.918 billion, ranking third in the global best-selling drug list, the list of heavyweight drugs, the number one AbbVie's Adamum monotonica, the second-ranked Mercato's Paboli Pearl, and the rankingAfter that doamine, Johnson's ibtinib, Schweipon/Ono Pharmaceuticals' Navuliu monogenated, Roche's Beval-Zhuszma, Pfizer-Schweppel's Apixab, Bayer-Regeneron's Abersip, Pfizer-Ajine's Inasip, Roche's LixitozumabAccording to statistics, the world's best-selling TOP10 drug sales totaled $94 billion - of which the top three products were: Adamu monoanti-drug $19.169 billion;It's worth noting that last year, it was also the first time that the country had entered the $10 billion clubAccording to the latest earnings data from New Base, sales of nadomine rose 11.8 percent from a year earlier The move follows new company's 2018 results showing sales of the company to $9,685 million in 2018, close to the $10 billion mark 　　Data show that in recent years, the global sales of nadomine has maintained double-digit growth, is the world's best-selling cancer drugs, the market potential is huge 　　According to the statistics of the world's best-selling drugs, in 2005, the sales performance of the new base of naratmine was only 0.03 billion U.S dollars, in 2007 exceeded $500 million, in 2008 exceeded $1 billion, in 2010 exceeded $2 billion, in 2012 exceeded $3 billion, in 2013 broke through 4 US$0 billion, usdd by US$5 billion in 2014, US$6 billion in 2015, US$7 billion in 2016, US$8 billion in 2017, US$9.685 billion in 2018 and US$10.823 billion in global sales in 2019 　　It is worth noting that with the increasing number of new indications, sales increase year by year, now, the inamine has become the small molecule anti-tumor drug field's number one heavy drug 　　2
, the domestic market 1-3 pattern appears: the new base, Shuangyi, Tianqing, Qilu up to now, to nadu amine listed in the domestic market in addition to the original research and pharmaceutical enterprises new base, there are three local pharmaceutical companies, respectively, Shuangyu Pharmaceuticals, Zhengda Qing, Qilu Pharmaceuticals 　　Beijing Shuangyu Pharmaceuticals was the first to obtain the drug registration
and new drug certificate for nadoamine capsules on November 21, 2017 　　The Nadoamine capsule was approved for sale in January 2019 (approved for 25mg) and approved for indications in line with the original drug On October 30 last year, positive day and day to nadoamine through the consistency evaluation 　　On November 21, 2019, China Biopharmaceuticals announced that its subsidiary, the anti-tumor drug Comenadoamine Capsule (commodity name "Anxian") was approved by the State Drug Administration for supplementation applications, adding 5mg and 10mg of two specifications Biopharma said the approval of the new specifications would enrich the Group's product line to meet different market needs 　　On May 9, 2019, Qilu Pharmaceuticals announced that the Nadoamine capsule "Zipuyi" (commodity name) was approved for the market, and is the first of its kind to pass a consistent evaluation of the product 　　From the above three enterprises approved, Beijing Shuangyi Pharmaceuticals listed as the earliest, in November 2017, and formally passed the consistency evaluation in June 2020; Up to now, the domestic approved three to nado amine capsule enterprises all through the consistency evaluation 　　Whether it is the selection of national drug varieties, or the relevant policy orientation of the domestic generic drug consistency evaluation, for chemicals, it makes the consistency evaluation enterprises full of 3 has become an important node and signal 　　Unlike the outstanding performance of the international market, the data of the mininet data show that the performance of nadoamine in the domestic market is not ideal, in 2013 to 2017, the market growth rate of nadoamine is not very fast, mainly subject to the high price of patented drugs, but has not yet entered health insurance 　　In July 2017, through state negotiations, nardomine was included in the 2017 version of the National Health Insurance Drug Catalog Category B range, the price from 2799 yuan (25 mg/grain) adjusted to 1101.99 yuan (25 mg/grain), followed by a significant market release, especially into 2019, the sales of nardomine capsules increased to 710 million yuan 　　In 2019, Xinji has a market share of 68.4%, Zhengda Qing has a 23.3% share and Beijing Shuangyu and Qilu Pharmaceuticals will have a market share of 8.34 percent, according to Minnet 　　In addition to the above four pharmaceutical companies, is declaring to that doamine is yangzijiang pharmaceutical, Howson Pharmaceuticals and other more than 10 well-known pharmaceutical companies, with more domestic pharmaceutical companies to declare the products listed, to nadoamine market competition situation may be further strained